NuCana (NCNA) Q3 2025 results; director Bali Muralidhar resigns

NuCana plc furnished a Form 6-K noting it issued a press release announcing third quarter 2025 financial results and provided accompanying materials.

Accepted by SEC EDGAR 11/13/2025 - 04:18 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NuCana plc furnished a Form 6-K noting it issued a press release announcing third quarter 2025 financial results and provided accompanying materials. The filing includes unaudited condensed consolidated financial statements as of September 30, 2025 (Exhibit 99.1), Management’s Discussion and Analysis for the three and nine months ended September 30, 2025 and 2024 (Exhibit 99.2), and the November 13, 2025 press release (Exhibit 99.3).

Exhibits 99.1 and 99.2 are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-281576) and Form S-8 (File Nos. 333-223476 and 333-248135). Exhibit 99.3 is being furnished and is not deemed filed. The Company also disclosed that, effective October 21, 2025, Bali Muralidhar, M.D., Ph.D. resigned from the Board and all committees; the resignation was not the result of any dispute regarding operations, policies, or practices.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NuCana (NCNA) disclose in this Form 6-K?

It furnished Q3 2025 financial materials, including unaudited financials (Ex. 99.1), MD&A (Ex. 99.2), and a press release (Ex. 99.3).

Which exhibits are incorporated by reference for NuCana (NCNA)?

Exhibits 99.1 and 99.2 are incorporated by reference into the Form F-3 (No. 333-281576) and Forms S-8 (Nos. 333-223476 and 333-248135).

Is NuCana’s Q3 2025 press release considered filed or furnished?

Exhibit 99.3 (press release) is being furnished and is not deemed filed under the Exchange Act.

What board change did NuCana (NCNA) announce?

Effective October 21, 2025, Bali Muralidhar, M.D., Ph.D. resigned from the Board and all committees.

Did the director resign due to a disagreement with NuCana?

No. The filing states the resignation was not the result of any dispute regarding operations, policies, or practices.

What periods do NuCana’s attached financials and MD&A cover?

They cover the three and nine months ended September 30, 2025 and 2024.

What is the date of NuCana’s Q3 2025 press release?

The press release is dated November 13, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

(Commission File No. 001-38215)

NUCANA PLC

(Translation of registrant’s name into English)

3 Lochside Way

Edinburgh EH12 9DT

United Kingdom

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐

Other Events

On November 13, 2025, NuCana plc (the “Company”) issued a press release announcing its third quarter 2025 financial results. The Company’s unaudited condensed consolidated financial statements as of September 30, 2025 are attached as Exhibit 99.1 and are incorporated by reference herein. The Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations is attached hereto as Exhibit 99.2, and is incorporated by reference herein. The press release is attached as Exhibit 99.3 hereto and is incorporated by reference herein.

The information in the attached Exhibits 99.1 and 99.2 shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (File Number 333-281576), and Form S-8 (File Number 333-223476 and File Number 333-248135), and related prospectuses, as such registration statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

The information in the attached Exhibit 99.3 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

Board of Directors Matters

Effective October 21, 2025, Bali Muralidhar, M.D., Ph.D. resigned from his role as a member of the Board of Directors (the “Board”) of the Company and all committees of the Board. Dr. Muralidhar’s resignation was not the result of any dispute with the Company or the Board on any matter relating to the operations, policies or practices of the Company.

Exhibits

Exhibit		Description
99.1		Unaudited Condensed Consolidated Financial Statements as of September 30, 2025 and for the Three and Nine Months Ended September 30, 2025 and 2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2025 and 2024
99.3		Press Release Dated November 13, 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

NuCana plc
By:		/s/ Ian Webster
Name:		Ian Webster
Title:		Interim Chief Financial Officer (Principal Financial and Accounting Officer)

Date: November 13, 2025